{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:48:12Z","timestamp":1761511692501},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6580,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1093\/annonc\/mdf006","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:59:57Z","timestamp":1027724397000},"page":"103-107","source":"Crossref","is-referenced-by-count":37,"title":["Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study"],"prefix":"10.1016","volume":"13","author":[{"given":"I.","family":"Monnet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"de Cremoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Souli\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Saltiel-Voisin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bekradda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Saltiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Brain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Rixe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Yataghene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-L.","family":"Misset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cvitkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf006_bb0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1006330030333","article-title":"Chemotherapy in non-small cell lung cancer","volume":"18","author":"Sweeney","year":"2000","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdf006_bb0015","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials","volume":"311","author":"Non-Small Cell Lung Cancer Collaborative Group","year":"1995","journal-title":"J Br Med"},{"key":"10.1093\/annonc\/mdf006_bb0020","first-page":"76","article-title":"The role of new agents in advanced non-small-cell lung carcinoma","volume":"2","author":"Langer","year":"2000","journal-title":"CurrOncol Rep"},{"key":"10.1093\/annonc\/mdf006_bb0025","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.1998.16.7.2459","article-title":"Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study","volume":"16","author":"Wozniak","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf006_bb0030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/oxfordjournals.annonc.a058687","article-title":"Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial","volume":"5","author":"Depierre","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf006_bb0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JCO.1994.12.2.360","article-title":"Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients","volume":"12","author":"Le Chevalier","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf006_bb0040","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.1990.8.8.1301","article-title":"Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small-cell lung cancer","volume":"8","author":"Jaakkimainen","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf006_bb0045","first-page":"16","article-title":"New insights into the cost-effectiveness of lung cancer treatment","volume":"9","author":"Evans","year":"1999","journal-title":"Oncology"},{"issue":"Abstr","key":"10.1093\/annonc\/mdf006_bb0050","first-page":"18","article-title":"A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) trial","volume":"461a","author":"Kelly","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr","key":"10.1093\/annonc\/mdf006_bb0055","first-page":"19","article-title":"An economic analysis of Southwest Oncology Group Trial S9509: cisplatin\/vinorelbine vs. carboplatin\/paclitaxel for advanced nonsmall cell lung cancer","volume":"489a","author":"Ramsey","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf006_bb0060","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1023\/A:1008213732429","article-title":"Oxaliplatin: a review of preclinical and clinical studies","volume":"9","author":"Raymond","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf006_bb0065","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0959-8049(98)00007-0","article-title":"Association pour le Traitement des Tumeurs Intra Thoraciques (ATTIT). Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC","volume":"34","author":"Monnet","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf006_bb0070","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1200\/JCO.2001.19.2.458","article-title":"Phase I\/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer","volume":"19","author":"Monnet","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf006_bb0075","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X","article-title":"A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump","volume":"69","author":"L\u00e9vi","year":"1992","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf006_bb0080","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1200\/JCO.2000.18.7.1451","volume":"18","author":"Comella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf006_bb0085","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2000.18.13.2529","article-title":"Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer","volume":"18","author":"Frasci","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Abstr","key":"10.1093\/annonc\/mdf006_bb0090","first-page":"41","article-title":"How to define the recommended dose based on the cumulative toxicity in combination Phase I studies: Example of the gemcitabine (DFDC)\u2013oxaliplatin (l-OHP) study in patients (pts) with advanced non-small-cell lung (NSCLC) and ovarian carcinoma (OC)","volume":"611","author":"Faivre","year":"2000","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdf006_bb0095","first-page":"25","article-title":"Phase I study of gemcitabine\/oxaliplatin combination in patients with advanced solid tumors: a preliminary report","volume":"27","author":"Mavroudis","year":"2000","journal-title":"Semin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419627560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419627560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/1\/103\/19479675\/103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:27:55Z","timestamp":1582183675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419627560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["S0923753419627560"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf006","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}